< Professor Minee Choi of the Department of Brain and Cognitive Sciences (top left). Professor Sonia Gandhi (top right) and Professor Klenerman of the University College London (bottom right) > Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, researchers at KAIST have revealed that RNA editing plays a crucial role in regulating neuroi
2025-05-02KAIST (President Kwang Hyung Lee) opened a special exhibition "The Vault of Masterpieces" featuring the architects of the Gallerist Hong Gyu Shin, who is active in New York, on April 29th. Since its opening in December 2024, the KAIST Museum of Art, which has mainly exhibited works from its own collection, has boldly invited internationally renowned gallerist Shin Hong-gyu to hold its first full-scale special exhibition, displaying a large number of his collections in the center of the campus
2025-04-30KAIST (President Kwang-Hyung Lee) announced on the 10th of April that it successfully promoted the world’s first ‘Space Sound Source Transmission Project’ based on media art at the KAIST Space Research Institute on April 9th through collaboration between Professor Jinjoon Lee of the Graduate School of Culture Technology, a world-renowned media artist, and the global K-Pop artist, G-Dragon. This project was proposed as part of the ‘AI Entertech Research Center’ be
2025-04-10KAIST (President Kwang-Hyung Lee) announced on the 9th that it will hold a signboard ceremony for the establishment of the ‘AI Entertech Research Center’ with the artificial intelligence entertech company, Galaxy Corporation (CEO Yong-ho Choi) at the main campus of KAIST. < (Galaxy Corporation, from center to the left) CEO Yongho Choi, Director Hyunjung Kim and related persons / (KAIST, from center to the right) Professor SeungSeob Lee of the Department of Mechanical Engineer
2025-04-09Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have revolutionized cancer treatment. However, fewer than 20% of patients respond to these treatments, highlighting the urgent need for new strategies tailored to both responders and non-responders. KAIST researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master regulator that hinders the effectiveness of immunotherapy—opening
2025-04-08